If you are a Healthcare Professional and you would like to log in to access this content, please click "Login".
You are now leaving the Lilly Medical Web site
The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Eli Lilly and Company does not control, influence, or endorse this site, and the opinions, claims or comments expressed on this site should not be attributed to Eli Lilly and Company. Eli Lilly and Company is not responsible for the privacy policy of any third party web sites. We encourage you to read the privacy policy of every web site you visit.
Menu closed
Please use a minimum of three unique search wordsOur search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Cialis ® (tadalafil)
This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. Please refer to the link for full prescribing information:
Cialis Summary of Product Characteristics (SmPC)
Cialis® (tadalafil): Visual defects
Cialis is contraindicated in patients who have loss of vision in one eye because of non-arteritic anterior ischaemic optic neuropathy (NAION)
Cialis is
contraindicated in patients who have loss of vision in one eye
because of NAION, regardless of whether this episode was in
connection or not with previous PDE5 inhibitor exposure.
Vision
Visual
defects and cases of NAION have been reported in connection with the
intake of Cialis and other PDE5 inhibitors. Analyses of observational
data suggest an increased risk of acute NAION in men with erectile
dysfunction following exposure to tadalafil or other PDE5 inhibitors.
As this may be relevant for all patients exposed to tadalafil, the
patient should be advised that in case of sudden visual defect, he
should stop taking Cialis and consult a physician immediately
REFERENCE
Cialis
[Summary of Product Characteristics]. Utrecht,
The Netherlands: Eli Lilly Nederland B.V.
Date of Last Review:September 26, 2018
Are you satisfied with this content?
Contact Lilly
Call or Email us
If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at ukmedinfo@lilly.com